IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ImmunityBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$8.42−0.76 (-8.28%)
Close on Oct 19, 2026
- Market cap
- $8.84B
- P/E (TTM)
- –
- Dividend yield
- –
ImmunityBio, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $164.89M | $140.64M | $112.98M | $81.92M | $56.09M | $30.66M | $14.15M | $6.94M | $990.00K | $0 | $0 | 99.5% | +194.0% |
| Other revenues | $901.00K | $337.00K | $306.00K | $639.00K | $510.00K | $563.00K | $595.00K | $388.00K | $318.00K | $302.00K | $622.00K | 0.5% | +76.7% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $164.97M | $140.68M | $113.01M | $81.96M | $56.15M | $30.72M | $14.21M | – | – | – | – | 99.5% | +193.8% |
| Europe | $820.00K | $302.00K | $278.00K | $597.00K | $455.00K | $506.00K | $531.00K | – | – | – | – | 0.5% | +80.2% |
From the segment and revenue-disaggregation notes of ImmunityBio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.